#

Prof. Dr. Gabriele Fischer

Director, Addiction Clinic, Center of Public Health and Department of Psychiatry & Psychotherapy, Medical University Vienna, Austria

#

Prof. Christoph U Correll, MD.

The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY, USA. Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine, Hempstead, NY, USA. Charité – Universitätsmedizin Berlin, Department of Child and Adolescent Psychiatry, Berlin, Germany.

In this discussion, Professors Christoph Correll and Gabriele Fischer address the complexities of treating patients with cooccurring schizophrenia and substance use disorders. The conversation covers the challenges of managing the comorbidity of these disorders.

Related content

description Article
Brain Insulin Action and Metabolic Dysregulation in Schizophrenia: From Mechanistic Insights to Novel Interventions

The complex interplay between metabolic dysfunction and brain insulin resistance in schizophrenia warrants further investigation as it represents a unique opportunity for both mechanistic inquiry and the development of novel therapeutic strategies that can improve metabolic and cognitive outcomes in this population.

24.10.2025 Schizophrenia
image Image
Central and peripheral causes of brain insulin resistance in schizophrenia

Central and peripheral causes of brain insulin resistance in schizophrenia

24.10.2025 Schizophrenia
image Image
Brain insulin action in relation to peripheral and central outcomes
24.10.2025 Schizophrenia